Breast cancer in 2017: Spurring science, marking progress, and influencing history
Breast cancer in 2017: Spurring science, marking progress, and influencing history, Published online: 12 December 2017; doi:10.1038/nrclinonc.2017.191Data published in 2017 underscore the benefit of optimizing anti-HER2 therapy in early stage high-risk HER2-positive disease, and of capecitabine in patients with residual disease after optimal neoadjuvant therapy. In the advanced-stage setting, endocrine therapy combined with cyclin-dependent kinase 4/6 inhibitors, or olaparib could become the preferred option. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 12, 2017 Category: Cancer & Oncology Authors: Jose Perez-Garcia Javier Cortes Source Type: research
Immunotherapy: New or second CARs for ALL
Immunotherapy: New or second CARs for ALL, Published online: 05 December 2017; doi:10.1038/nrclinonc.2017.193Immunotherapy: New or second CARs for ALL (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 5, 2017 Category: Cancer & Oncology Authors: David Killock Source Type: research
Lung cancer: Osimertinib strengthens the frontline
Lung cancer: Osimertinib strengthens the frontline, Published online: 05 December 2017; doi:10.1038/nrclinonc.2017.192Lung cancer: Osimertinib strengthens the frontline (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 5, 2017 Category: Cancer & Oncology Authors: David Killock Source Type: research
Urothelial cancer in 2017: Changes in expectations for metastatic urothelial carcinoma
Urothelial cancer in 2017: Changes in expectations for metastatic urothelial carcinoma, Published online: 05 December 2017; doi:10.1038/nrclinonc.2017.1842017 saw the publication of clinical trial data and the approval of new treatment approaches for metastatic urothelial carcinoma. Pembrolizumab is now a well-established treatment for patients with disease progression after cisplatin, with high-level evidence supporting its superiority over second-line chemotherapy. For patients ineligible for cisplatin, atezolizumab and pembrolizumab provide meaningful clinical benefit as frontline therapies. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 5, 2017 Category: Cancer & Oncology Authors: Joaquim Bellmunt Rosa Nadal Source Type: research
Immunotherapy: Relying on quality over quantity
Immunotherapy: Relying on quality over quantity, Published online: 28 November 2017; doi:10.1038/nrclinonc.2017.189Immunotherapy: Relying on quality over quantity (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 28, 2017 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Colorectal cancer in 2017: Practice-changing updates in the adjuvant and metastatic setting
Colorectal cancer in 2017: Practice-changing updates in the adjuvant and metastatic setting, Published online: 28 November 2017; doi:10.1038/nrclinonc.2017.1852017 has been full of new discoveries that will influence the treatment of colorectal cancer. In the adjuvant setting, 3 months of chemotherapy might now be considered a new standard of care. Various other new treatments and promising biomarkers have also become available that will improve survival outcomes and the quality of life of many patients with metastatic disease. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 28, 2017 Category: Cancer & Oncology Authors: Alberto Puccini Heinz-Josef Lenz Source Type: research
Melanoma in 2017: Moving treatments earlier to move further forwards
Melanoma in 2017: Moving treatments earlier to move further forwards, Published online: 28 November 2017; doi:10.1038/nrclinonc.2017.183In 2017, results from phase III trials demonstrated the impressive safety and efficacy of adjuvant targeted and immune therapies in patients with resectable stage III–IV melanoma, and raised questions about the surgical management of patients with microscopic sentinel-lymph-node metastases. For patients with unresectable disease, new overall survival data added to the debate about the relative benefits of single-agent anti-PD-1 versus combined anti-PD-1 and anti-CTLA-4 immunotherapy. (So...
Source: Nature Clinical Practice Oncology - November 28, 2017 Category: Cancer & Oncology Authors: Michael A. Davies Keith T. Flaherty Source Type: research
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes, Published online: 28 November 2017; doi:10.1038/nrclinonc.2017.188Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 28, 2017 Category: Cancer & Oncology Authors: Alexander Drilon Zishuo I. Hu Gillianne G. Y. Lai Daniel S. W. Tan Source Type: research
Me too-drugs with limited benefits — the tale of regorafenib for HCC
Me too-drugs with limited benefits — the tale of regorafenib for HCC, Published online: 28 November 2017; doi:10.1038/nrclinonc.2017.190Me too-drugs with limited benefits — the tale of regorafenib for HCC (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 28, 2017 Category: Cancer & Oncology Authors: Bishal Gyawali Vinay Prasad Source Type: research
Lung cancer in 2017: Giant steps and stumbling blocks
Lung cancer in 2017: Giant steps and stumbling blocks, Published online: 21 November 2017; doi:10.1038/nrclinonc.2017.178In 2017, major advances in the treatment of non-small-cell lung cancer (NSCLC) continued to emanate from the fields of molecularly targeted therapy and immunotherapy. In the former, new drugs with improved efficacy and reduced toxicity entered the clinic; in the latter, immune-checkpoint inhibition proved efficacious after chemoradiotherapy for stage III disease, but had disparate results in the frontline treatment of stage IV disease. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 21, 2017 Category: Cancer & Oncology Authors: David F. Heigener Martin Reck Source Type: research
Immunotherapy: Gut bacteria modulate responses to PD-1 blockade
Immunotherapy: Gut bacteria modulate responses to PD-1 blockade, Published online: 21 November 2017; doi:10.1038/nrclinonc.2017.182 (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 21, 2017 Category: Cancer & Oncology Authors: David Killock Source Type: research
Disseminated breast tumour cells: biological and clinical meaning
Disseminated breast tumour cells: biological and clinical meaning, Published online: 21 November 2017; doi:10.1038/nrclinonc.2017.174We posit that disseminating tumour cells detected in the bone marrow or in the circulation are either cancer stem cells with full metastatic potential, tumour-bulk cells, or dormant cancer cells. This model has both therapeutic and diagnostic implications, raising concern over inadequate treatment as well as the possibility of overtreatment resulting from overdiagnosis. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 21, 2017 Category: Cancer & Oncology Authors: Klaus Pantel Daniel F. Hayes Source Type: research
Surgical oncology for gliomas: the state of the art
Surgical oncology for gliomas: the state of the art, Published online: 21 November 2017; doi:10.1038/nrclinonc.2017.171Surgery remains the mainstay of treatment for patients with gliomas, independent of tumour grade, and maximal resection of the tumour is essential for long-term disease control. Herein, the authors discuss the current evidence on associations between the extent of glioma resection and clinical outcomes. They also describe the state-of-the-art surgical oncology approaches aimed at maximizing the extent of tumour resection while minimizing patient morbidity. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 21, 2017 Category: Cancer & Oncology Authors: Nader Sanai Mitchel S. Berger Source Type: research
Lung cancer 2017: Giant steps and stumbling blocks
Lung cancer 2017: Giant steps and stumbling blocks, Published online: 21 November 2017; doi:10.1038/nrclinonc.2017.178In 2017, major advances in the treatment of non-small-cell lung cancer (NSCLC) continued to emanate from the fields of molecularly targeted therapy and immunotherapy. In the former, new drugs with improved efficacy and reduced toxicity entered the clinic; in the latter, immune-checkpoint inhibition proved efficacious after chemoradiotherapy for stage III disease, but had disparate results in the frontline treatment of stage IV disease. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 21, 2017 Category: Cancer & Oncology Authors: David F. Heigener Martin Reck Source Type: research
Targeted therapies: Precision medicine for ATC — BRAF and MEK inhibition shows promise
Targeted therapies: Precision medicine for ATC — BRAF and MEK inhibition shows promise, Published online: 17 November 2017; doi:10.1038/nrclinonc.2017.181 (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - November 17, 2017 Category: Cancer & Oncology Authors: David Killock Source Type: research
